$heff's $tation of $tocks & $olid DD

[My 2 Cents]

Posted by: 2morrowsGains Date: Thursday, June 25, 2009 3:07:12 PM
In reply to: None Post # of 942

AEMD...Aethlon Medical's presentation notes...

Aethlon Medical presented at the Redchip Conference last week in Fort Lauderdale and IMO has more upside potential than all the other presenting companies put together. Only time will tell, but with a share price of $0.24 and a market cap of approx $15M, this company (stock) is DEFINITELY one for the watch list IMO!
Aethlon Medical has a product called the "Hemopurifier" that is now entering commercialization phase and it is surpassing the results of Vertex's (VRTX) HEP-C drug Telaprevir! (I believe Telaprevir is still a year or two away from being commercialized).
Vertex has a current market cap of $6B. Aethlon's market cap is approx $15M. Aethlon's CEO James Joyce calls it "an amazing phenomenon" regarding Aethlon's market value vs Vertex..."Hopefully that will adjust somewhat in the near future."

The comments and notes in this post are my opinion based on Aethlon Medical's Redchip (March & June) presentations. Here are the links to the presentations along with my notes...

June (Ft Lauderdale) Presentation w/ PowerPoint...
http://www.redchip.com/visibility/conferencePages/FTLauderdale2009/conferenceMain.asp?page=archive#

March (San Fransisco) Presentation...
http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archive

"Aethlon Medical has a broad spectrum therapeutic device called the Hemopurifier. It's a multi-patented device that provides the ability to clear infectious viruses and amino suppressive proteins from circulation before the occurrence of cell and organ infection."

- "We believe the Hemopurifier is not just the leading broad spectrum candidate to treat bio-terror and pandemic threats, based on clinical data we think it's the only broad spectrum candidate to treat these threats."

- Now transitioning from a lengthy R&D phase and proof of principle phase, which included animal studies and human studies, into the commercialization phase!

- The technology has proven effective in treating Hepatitis C virus, HIV, and has demonstrated the ability to capture bio-terror threats and pandemic threats.
Aethlon believes they can dramatically increase cure rates in HEP-C, perhaps up to 90%!

- "We are establishing the industry to treat infectious disease and cancer with therapeutic filtration devices."

- Aethlon recently entered into an agreement to establish GMP manufacturing...
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1262531&highlight=
Expects product to start coming off the line towards the end of Q3 this year.

- Wants to establish Hemopurifier clinic sites in the U.S. and treatment centers India.

- "We are right now negotiating strategic partnerships related to expansive manufacturing, clinical partnerships, and development partnerships here in the U.S., and we are also involved in discussing partnerships with organizations that can provide future development of our technology, both as a portable device, and with applications into other fields."

- "At present our market cap is under $15M, but yet it's the only single therapy able to address bio-terror threats, HIV and Hepatitis C."
In the bio-terror and pandemic space, it's the leading broad spectrum candidate against these pathogens.
In HIV, it provides the solution to manage disease progression once patients become resistant to their drug regimens.
"In Hepatitis C, I believe it's going to soon be considered a leading adjunct candidate."

- The Hemoprifier is a single use disposable cartridge designed for use in conjunction with portable pumps and within the global infrastructure of dialysis machines already located in hospitals and clinics worldwide.
It acts as an artificial adjunct to the immune system, to inhibit progression of infectious and to improve treatment outcomes in cancer.

- In infectious disease it works to clear viruses before they can affect organs and cells by interrupting the replication process.
And the cartridge is also proven to remove amino suppressive proteins that are shed from the viruses that kill off immune cells.

- "We have also discovered that the cartridge has the ability to remove proteins that are secreted by tumors in cancer, that are known to kill off the immune system. So we have an amino therapeutic benefit in cancer therapy."

- "At this point in time, we're initializing commercialization overseas in practitioner driven markets. And something that's very crucial to point out, we are now entering our second decade of development. In terms of commercialization, our shareholders own 100% of the Hemopurifier. And this is very rare for a micro cap or small cap company. Usually by this phase there was a need or requirement to license out the technology, or to co-develop the technology which costs rights to the technology. So in this rare case, we actually own 100% of the technology as it moves toward marketplace."

- Aethlon Medical has only presented their information to a few analysts, the same analysts that cover Vertex and other players in the market. They have yet to come accros an analyst that was aware of the information. "But the analysts we have talked to concur, this could change the entire game and could be the cause to re-evaluate evaluations in the space."

- "While we're not known on Wall Street yet, patients know us. And I think that at the end of the day, value in our company is not going to be driven by bloggers, day traders, analysts and so on. It's going to be driven by patient demand and acceptance in the marketplace."

NBC report from March 2007...

CNN Report from July 2007...

Aethlon Medical Inc. web site...
http://www.aethlonmedical.com/

Letter to the shareholders...
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1297905&highlight=

Recent news...
http://www.aethlonmedical.com/news/

I am certainly not an expert here and there are a few things I don't quite understand, but IMO AEMD has ENORMOUS upside potential and is DEFINITELY one to put on the watch list!!

All notes posted above are based on my opinion and should be re-checked by listening to AEMD's Redchip presentations.